Equities research analysts forecast that Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) will announce sales of $22.90 million for the current quarter, Zacks Investment Research reports. Five analysts have issued estimates for Alnylam Pharmaceuticals’ earnings. The lowest sales estimate is $17.10 million and the highest is $37.00 million. Alnylam Pharmaceuticals posted sales of $17.45 million during the same quarter last year, which suggests a positive year over year growth rate of 31.2%. The firm is expected to announce its next quarterly earnings results on Wednesday, February 14th.
On average, analysts expect that Alnylam Pharmaceuticals will report full-year sales of $22.90 million for the current financial year, with estimates ranging from $56.59 million to $94.36 million. For the next financial year, analysts expect that the business will post sales of $102.17 million per share, with estimates ranging from $2.97 million to $137.00 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research analysts that follow Alnylam Pharmaceuticals.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($1.34) EPS for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.11). Alnylam Pharmaceuticals had a negative return on equity of 46.94% and a negative net margin of 664.70%. The company had revenue of $17.10 million for the quarter, compared to analyst estimates of $28.15 million. During the same period last year, the firm earned ($1.21) earnings per share. The firm’s revenue for the quarter was up 24.8% on a year-over-year basis.
ALNY has been the subject of a number of research analyst reports. B. Riley initiated coverage on Alnylam Pharmaceuticals in a research note on Wednesday, November 1st. They issued a “buy” rating and a $240.00 target price for the company. Credit Suisse Group boosted their target price on Alnylam Pharmaceuticals from $123.00 to $151.00 and gave the company an “outperform” rating in a research note on Friday, November 3rd. Stifel Nicolaus reissued a “buy” rating and issued a $56.00 target price (up from $47.00) on shares of Alnylam Pharmaceuticals in a research note on Thursday, August 10th. Cowen and Company restated a “buy” rating and issued a $151.00 price target on shares of Alnylam Pharmaceuticals in a report on Thursday. Finally, Chardan Capital restated a “buy” rating and issued a $124.00 price target (down from $131.00) on shares of Alnylam Pharmaceuticals in a report on Thursday, August 10th. Three analysts have rated the stock with a sell rating, six have assigned a hold rating and seventeen have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $114.57.
In other Alnylam Pharmaceuticals news, President Barry E. Greene sold 85,316 shares of the stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $125.00, for a total transaction of $10,664,500.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, President Barry E. Greene sold 76,815 shares of the firm’s stock in a transaction dated Wednesday, September 20th. The shares were sold at an average price of $100.00, for a total value of $7,681,500.00. Following the completion of the sale, the president now owns 165,399 shares of the company’s stock, valued at $16,539,900. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 215,797 shares of company stock valued at $25,035,072. 4.30% of the stock is owned by corporate insiders.
Several institutional investors and hedge funds have recently modified their holdings of the company. FMR LLC grew its stake in shares of Alnylam Pharmaceuticals by 6.3% in the 2nd quarter. FMR LLC now owns 13,723,153 shares of the biopharmaceutical company’s stock valued at $1,094,559,000 after buying an additional 815,270 shares during the period. Vanguard Group Inc. grew its stake in shares of Alnylam Pharmaceuticals by 13.4% in the 2nd quarter. Vanguard Group Inc. now owns 6,419,508 shares of the biopharmaceutical company’s stock valued at $512,020,000 after buying an additional 759,295 shares during the period. BlackRock Inc. grew its stake in shares of Alnylam Pharmaceuticals by 9.3% in the 2nd quarter. BlackRock Inc. now owns 5,188,191 shares of the biopharmaceutical company’s stock valued at $413,811,000 after buying an additional 441,957 shares during the period. Baillie Gifford & Co. grew its stake in shares of Alnylam Pharmaceuticals by 2.9% in the 2nd quarter. Baillie Gifford & Co. now owns 3,431,316 shares of the biopharmaceutical company’s stock valued at $273,681,000 after buying an additional 96,805 shares during the period. Finally, First Trust Advisors LP grew its stake in shares of Alnylam Pharmaceuticals by 25.3% in the 3rd quarter. First Trust Advisors LP now owns 784,619 shares of the biopharmaceutical company’s stock valued at $92,185,000 after buying an additional 158,288 shares during the period. Institutional investors own 94.20% of the company’s stock.
TRADEMARK VIOLATION WARNING: “$22.90 Million in Sales Expected for Alnylam Pharmaceuticals, Inc. (ALNY) This Quarter” was originally posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this report can be accessed at https://stocknewstimes.com/2017/11/11/22-90-million-in-sales-expected-for-alnylam-pharmaceuticals-inc-alny-this-quarter.html.
Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) traded up $2.30 during trading on Wednesday, hitting $139.98. The company had a trading volume of 1,386,900 shares, compared to its average volume of 1,120,946. The company has a quick ratio of 8.84, a current ratio of 9.83 and a debt-to-equity ratio of 0.14. Alnylam Pharmaceuticals has a twelve month low of $35.98 and a twelve month high of $147.63.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.